Trends in 12-Month Mortality and Statutory Health Insurance Costs in Incident Metastatic Bladder Cancer in Germany, 2011–2024
In incident metastatic bladder cancer in Germany, costs per patient rose from €32,245 to €43,042 between 2011 and 2024, without any improvement in 12-month survival.
Rising Drug Costs With Stable 12-Month Survival in Incident Metastatic Breast Cancer in Germany, 2011–2024
In incident metastatic breast cancer in Germany, 12-month survival remained broadly stable from 2011 to 2024, while costs rose by 22.9%, driven by outpatient drugs.
Trends in 12-Month Mortality and Healthcare Costs in Incident Metastatic Colorectal Cancer in Germany, 2011–2024
In incident metastatic colorectal cancer in Germany, costs rose moderately (+17.2%) between 2011 and 2024 without a consistent improvement in 12-month survival.
Increasing Costs and Limited Mortality Improvement in Incident Metastatic Lung Cancer in German Statutory Health Insurance Claims, 2011–2024
Costs for incident metastatic lung cancer in Germany rose by 87.5% between 2011 and 2024, while 12-month survival improved only modestly and inconsistently.
More Than Doubling of Costs With Unchanged 12-Month Mortality in Incident Metastatic Prostate Cancer in Germany, 2011–2024
Costs per patient with incident metastatic prostate cancer in Germany more than doubled between 2011 and 2024 – while 12-month survival remained nearly unchanged.
Epidemiology, Clinical Burden and Inflammatory Marker Testing in Atherosclerotic Cardiovascular Disease and Symptomatic Heart Failure in Germany: Insights from the ACHILLES Claims Data Analysis
How large is the burden of atherosclerotic cardiovascular disease (ASCVD) and symptomatic heart failure (HF) in Germany today – and how often is inflammation actually tested in routine care?
The ACHILLES claims data analysis, based on GWQ ServicePlus data from approximately 7.8 million individuals (2020–2024), identified 173,327 incident ASCVD and 121,208 incident symptomatic HF patients. In 2023, the age- and sex-adjusted incidence was 779 (ASCVD) and 668 (HF) per 100,000 individuals. Within 24 months, one in three ASCVD patients and almost one in two HF patients had a CV-related hospitalization – yet CRP testing was observed in only about 40% of patients in the first year after diagnosis.
ECA Feasibility Questionnaire: Quick Self-Evaluation
De-risk your evidence generation process by quickly assessing the feasibility of your External Comparator Arm (ECA). Identifying potential gaps early saves both time and financial resources.
This 24-question check evaluates three critical domains:
General Strategy (2 questions)
Data Feasibility (13 questions)
Design Feasibility (9 questions)
Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE COV19 Study, September 2022 to March 2024
Is there evidence for the benefit of COVID vaccinations in todays’ times? Recent study provides answers!
A team of scientists including GIPAM colleagues used GER claims data from GWQ Service Plus to explore what the impact of COVID-19 seasonal vaccinations between 1 September and 30 November 2023 is in an observational period of 4 months. A total of 146,132 individuals (73,066 vaccinated / 73,066 not vaccinated, 1:1 propensity score matching) were compared. All-cause mortality was 25% lower among COVID-19-vaccinated individuals (HR: 0.76; 95% CI: 0.70–0.82). Direct and indirect healthcare costs were found to be lower as well. These real-world findings support continued implementation of national immunisation recommendations during the endemic phase of SARS-CoV-2 circulation.
Trends in Epidemiology and Mortality of Patients with Bladder Cancer in Germany: A Retrospective Study Using German Claims Data
Despite progress in the detection and treatment of bladder cancer (BC), it remains one of the common cancer diagnoses. Updated estimates of its epidemiology and mortality are needed to better understand the BC burden in Germany. This research aims to estimate the incidence/prevalence of BC in Germany and to describe trends in mortality in the last eleven years.
Monitoring the Burden of Lung Cancer in Germany: Trends in Incidence and Survival Using ZfKD Registry Data (2020–2023)
OBJECTIVES: To describe recent trends in lung cancer incidence, staging, morphology, and survival outcomes in Germany using comprehensive population-based data from the German Centre for Cancer Registry Data (ZfKD).
METHODS: This retrospective analysis included all lung cancer cases diagnosed from 2020 to 2023 in individuals aged 18 years or older. Anonymized data were sourced from the ZfKD, which compiles mandatory cancer notifications across the German federal states. Variables analyzed included patient demographics, tumor characteristics (histological subtype, stage), and Kaplan-Meier-based survival estimates stratified by cancer subtype and stage.
RESULTS: A total of 222,366 lung cancer cases were recorded, with incidence per 100 adults of 0.081, 0.082, 0.081, and 0.077 in 2020, 2021, 2022, and 2023, respectively. Non-small cell lung cancer (NSCLC) accounted for 82.6% of cases, while small cell lung cancer (SCLC) made up 13.8%. NSCLC patients were older at diagnosis than those with SCLC (mean 70.2 vs. 68.5 years). Stage IV was the most common at diagnosis (41% in NSCLC, 59% in SCLC). Median survival was 12.8 months for NSCLC and 8.1 months for SCLC, dropping to 6.5 and 6.8 months, respectively, in stage IV disease. Adenocarcinoma was the most frequent NSCLC subtype (40.5%), followed by squamous cell carcinoma (15.7%).
CONCLUSION: Late-stage lung cancer diagnosis remains common and contributes to poor short-term survival. These findings underscore the need for earlier detection strategies and continued research into treatment pathways and outcomes.
GIPAM’s Unique Tool for Assessing the Feasibility of an External Control Arm Study
External control arms (ECAs) are used to generate comparative evidence (e.g., effectiveness) when only a single-arm trial has been conducted during the drug development process. However, key stakeholders often face substantial delays in determining the feasibility of an ECA; a responsive tool could streamline this process in a structured, rigorous manner.
Real-World DMARD Utilization in PsA and axSpA: Swedish & German Insights
Analysis of real-world data from Swedish National Registers (2017–2021) and a German insurance claims database (2018–2021) to assess characteristics and dosing patterns in PsA and axSpA patients initiating b/tsDMARDs. Included: 9414 PsA and 7763 axSpA patients in Sweden; 2045 PsA and 1756 axSpA patients in Germany. Despite alignment with European treatment guidelines, treatment patterns differed notably between countries. Further analysis comparing outcomes is warranted to determine real-world effectiveness of divergent approaches.
Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists
This German claims data study included continuously insured persons with at least two outpatient diagnoses and/or one inpatient diagnosis of T2DM if they started EMPA, DPP-4i, or GLP-1-RA in 2015–2018. Healthcare costs were assessed from therapy initiation until the end of data availability, death, or therapy discontinuation and compared among propensity score matched cohorts. Although the individual clinical patient profile and physician assessment are paramount in treatment decisions, substantial differences in the economic impact of different antidiabetic therapies should be considered.
Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany
Anonymized claims data of patients ≥18 years treated with drugs for cardiovascular (CV)-related diseases either as a single pill combination or multi-pill combination were evaluated. After propensity score matching, 59,336 out of 1,369,840 patients were analyzed. In all cohorts, patients receiving a single pill combination had a lower frequency of general practitioner and specialist visits. The patients also had a significantly lower ratio of all-cause hospitalization days and number of CV-related prescriptions as well as all-cause prescriptions (with one exception) compared with those receiving a multi-pill combination.
Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study
In an explorative study, we analyzed anonymized claims data sets of patients treated with CV drugs for hypertension and/or CV disorders who were insured by the German AOK PLUS statutory health fund covering 01/07/2012-30/06/2018. Patients aged ≥18 years who received either an SPC or MPC with identical drugs were followed for up to one year. A one-to-one propensity score matching (PSM) was applied within patient groups who started identical drug combinations, and results were reported as incidence rate ratios (IRRs) as well as hazard ratios (HRs). After PSM, data from 59,336 patients were analyzed. In 30 out of 56 IRR analyses, the superiority of SPC over MPC was shown. In 5 out of 7 comparisons, the HR for the composite outcome of all-cause death and all-cause hospitalizations was in favor of the SPC regimen.
Epidemiology, Diagnostics, and Treatment of Narcolepsyin Germany: The DORMIO Study
This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany.
Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1Receptor Agonists: A Retrospective Analysis
We used two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012) to assess the level of persistence and adherence to therapy with glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes mellitus (T2DM) patients in the United Kingdom (UK) and Germany, also by comparing once- (OD) with twice-a-day (BID) therapy.